We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
Read MoreHide Full Article
Atara Biotherapeutics, Inc. (ATRA - Free Report) announced an important update regarding the regulatory pathway for the impending biologics license application (BLA) submission for the company’s lead product candidate, tabelecleucel (tab-cel), in the United States.
Per the press release, Atara and the FDA have reached an alignment regarding the analytical comparability between manufacturing process versions of tab-cel. This alignment allows ATRA to include data regarding different process versions of tab-cel, from its pivotal phase III ALLELE study of the candidate, in the regulatory filing seeking approval for the same.
ATRA expects the BLA submission for tab-cel in the second quarter of 2024, which will include the latest tab-cel pivotal ALLELE study data.
The company’s stock rose 11.4% on Wednesday, in response to the encouraging news. Year to date, shares of Atara have plunged 46.3% compared with the industry’s 14.2% fall.
Image Source: Zacks Investment Research
Tab-cel is the company’s novel T-cell immunotherapy, which is currently being evaluated in the late-stage ALLELE study, for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
EBV+ PTLD is a rare hematologic malignancy (blood cancer) with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression.
EBV+ PTLD impacts two types of patients — those who have undergone solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT). The median survival of 0.7 months and 4.1 months for HCT and SOT patients, respectively, after failing standard-of-care treatment, is extremely poor. This represents a serious unmet medical need.
Tabelecleucel received marketing authorization from the European Commission in December 2022, as a monotherapy for the treatment of adult and pediatric patients aged two years and older with relapsed or refractory EBV+ PTLD who have received at least one prior therapy. It is currently marketed in the EU under the brand name, Ebvallo.
Atara is also looking to expand tab-cel’s indication. The company’s phase II multi-cohort study is currently evaluating tab-cel in other EBV-associated diseases, expecting to report top-line results in the fourth quarter of 2023.
Beside tab-cel, Atara has other candidates in its pipeline, which are currently under early-stage development in cancer and autoimmune disease indications.
Some better-ranked stocks in the overall medical sector, worth mentioning, are Dynavax Technologies (DVAX - Free Report) , Corcept Therapeutics (CORT - Free Report) and Better Therapeutics (BTTX - Free Report) , each carrying a Zacks Rank #2 (Buy) at present.
In the past 30 days, the Zacks Consensus Estimate for Dynavax’s 2023 loss per share has narrowed from 24 cents to 23 cents. The estimate for Dynavax’s 2024 earnings per share is currently pegged at 3 cents. Year to date, shares of DVAX have risen by 26.8%.
DVAX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 25.78%.
In the past 30 days, the Zacks Consensus Estimate for Corcept’s 2023 earnings per share has remained constant at 78 cents. The estimate for Corcept’s 2024 earnings per share has also remained constant at 83 cents. Year to date, shares of CORT have climbed 57.8%.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
In the past 30 days, the Zacks Consensus Estimate for Better Therapeutics’ 2023 loss per share has remained constant at 98 cents. During the same period, Better Therapeutics’ 2024 loss per share has also remained constant at 80 cents. Year to date, shares of BTTX have lost 63.8%.
BTTX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 24.22%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
Atara Biotherapeutics, Inc. (ATRA - Free Report) announced an important update regarding the regulatory pathway for the impending biologics license application (BLA) submission for the company’s lead product candidate, tabelecleucel (tab-cel), in the United States.
Per the press release, Atara and the FDA have reached an alignment regarding the analytical comparability between manufacturing process versions of tab-cel. This alignment allows ATRA to include data regarding different process versions of tab-cel, from its pivotal phase III ALLELE study of the candidate, in the regulatory filing seeking approval for the same.
ATRA expects the BLA submission for tab-cel in the second quarter of 2024, which will include the latest tab-cel pivotal ALLELE study data.
The company’s stock rose 11.4% on Wednesday, in response to the encouraging news. Year to date, shares of Atara have plunged 46.3% compared with the industry’s 14.2% fall.
Image Source: Zacks Investment Research
Tab-cel is the company’s novel T-cell immunotherapy, which is currently being evaluated in the late-stage ALLELE study, for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
EBV+ PTLD is a rare hematologic malignancy (blood cancer) with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression.
EBV+ PTLD impacts two types of patients — those who have undergone solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT). The median survival of 0.7 months and 4.1 months for HCT and SOT patients, respectively, after failing standard-of-care treatment, is extremely poor. This represents a serious unmet medical need.
Tabelecleucel received marketing authorization from the European Commission in December 2022, as a monotherapy for the treatment of adult and pediatric patients aged two years and older with relapsed or refractory EBV+ PTLD who have received at least one prior therapy. It is currently marketed in the EU under the brand name, Ebvallo.
Atara is also looking to expand tab-cel’s indication. The company’s phase II multi-cohort study is currently evaluating tab-cel in other EBV-associated diseases, expecting to report top-line results in the fourth quarter of 2023.
Beside tab-cel, Atara has other candidates in its pipeline, which are currently under early-stage development in cancer and autoimmune disease indications.
Atara Biotherapeutics, Inc. Price and Consensus
Atara Biotherapeutics, Inc. price-consensus-chart | Atara Biotherapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Atara currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall medical sector, worth mentioning, are Dynavax Technologies (DVAX - Free Report) , Corcept Therapeutics (CORT - Free Report) and Better Therapeutics (BTTX - Free Report) , each carrying a Zacks Rank #2 (Buy) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, the Zacks Consensus Estimate for Dynavax’s 2023 loss per share has narrowed from 24 cents to 23 cents. The estimate for Dynavax’s 2024 earnings per share is currently pegged at 3 cents. Year to date, shares of DVAX have risen by 26.8%.
DVAX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 25.78%.
In the past 30 days, the Zacks Consensus Estimate for Corcept’s 2023 earnings per share has remained constant at 78 cents. The estimate for Corcept’s 2024 earnings per share has also remained constant at 83 cents. Year to date, shares of CORT have climbed 57.8%.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
In the past 30 days, the Zacks Consensus Estimate for Better Therapeutics’ 2023 loss per share has remained constant at 98 cents. During the same period, Better Therapeutics’ 2024 loss per share has also remained constant at 80 cents. Year to date, shares of BTTX have lost 63.8%.
BTTX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 24.22%.